The rise of Viagra and its effect on the pharmaceutical landscape presents a complicated question for shareholders. While the first sales figures were astounding, the patent has expired, leading to a wave of copycat alternatives that are reducing earnings. In addition, the industry is facing issues related to population trends and evolving healthca